Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment (Q40762705)

23 September 2017

Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment (English)

1 reference

23 September 2017

Jeandidier N

1

1 reference

PubMed ID

10837697

23 September 2017

Boivin S

series ordinal

2

1 reference

PubMed ID

10837697

23 September 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

Advanced Drug Delivery Reviews

23 September 2017

1 reference

23 September 2017

35

1 reference

23 September 2017

2-3

1 reference

23 September 2017

179-198

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Excess costs of medical care for patients with diabetes in a managed care population

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

The cost to health plans of poor glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intensive insulin therapy in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Future developments in insulin delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Influence of insulin pen injection frequency on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

NPH insulin administration by means of a pen injector.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Influence of intensified insulin regimen on quality of life and metabolic control in insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Use of the pen delivery system for intensive insulin therapy in college-age students with type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin pens in elderly diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effect of patient-selected intensive insulin therapy on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Evaluation of the insulin jet injector as a potential source of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Jet-injected insulin is associated with decreased antibody production and postprandial glucose variability when compared with needle-injected insulin in gestational diabetic women.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Painfulness of needle and jet injection in children with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Risks of jet injection of insulin in children

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

The Medi-Jector II: efficacy and acceptability in insulin-dependent diabetic patients with and without needle phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Human insulin-induced lipoatrophy. Successful treatment using a jet-injection device

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Alteration of the risk factor paradigm for discontinuance of insulin pump therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Severe autonomic neuropathy treated with subcutaneous insulin infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Remission of severe hypoglycemic incidents in young diabetic children treated with subcutaneous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Severe lipoatrophy with human insulin: successfully treated by CSII

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Severe or life-threatening hypoglycemia in insulin pump treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Quality control in patient self-monitoring of blood glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Are presently available insulin analogues clinically beneficial?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin-like growth factor I therapy for diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Does C-peptide have a physiological role?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

C-peptide revisited--new physiological effects and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Prevention of vascular and neural dysfunction in diabetic rats by C-peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

The kinetics of peritoneal insulin absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin absorption after long-term intraperitoneal insulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Chronic continuous intraperitoneal insulin infusion (CIPII) in type I diabetic patients non-satisfactorily responsive to continuous subcutaneous insulin infusion (CSII)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Chemical stability of insulin in a delivery system environment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Clinical trial of programmable implantable insulin pump for type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabète du Traitement par Implants Actifs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Evadiac Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Normalization of Composition of Triglyceride-Rich Lipoprotein Subfractions in Diabetic Subjects During Insulin Infusion With Programmable Implantable Medication System

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin delivery decreases the levels of chylomicron remnants in patients with IDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin administration does not modify plasminogen activator inhibitor 1 levels in IDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

SHBG (sex hormone binding globulin) levels in insulin dependent diabetic patients according to the route of insulin administration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Catheter complications associated with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors, and obstructing materials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Pathogenesis and prevention of adhesion formation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Metabolic consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Immunogenicity and allergenic potential of animal and human insulins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Five cases of hyperthyroidism in type I diabetic patients treated with intraperitoneal insulin infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Pressure dermatitis from an implanted pacemaker.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Noninvasive blood glucose monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Non-invasive glucose monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Advances and prospects in glucose assay technology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Artificial pancreas, glucose sensors and the impact upon diabetology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Combination of microdialysis and glucose sensor for continuous on line measurement of the subcutaneous glucose concentration: theory and practical application

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Dermal interstitial glucose as an indicator of ambient glycemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Implantation of non-toxic materials from glucose sensors: evidence for specific antibodies detected by ELISA.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Alternative insulin delivery systems: how demanding should the patient be?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Algorithms for adjustment of insulin dosage by patients who monitor blood glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin dosage adjustment using manual methods and computer algorithms: a comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Application of computers in diabetes care--a review. II. Computers for decision support and education

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Artificial endocrine pancreas and optimal blood glucose regulation in diabetic patients--from bedside-type to wearable-type

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

10.1016/S0169-409X(98)00072-6

Identifiers

DOI

1 reference

23 September 2017

1 reference

PubMed ID

10837697